OTC Medicines

Browse OTC Medicines Content

CHPA submits these comments on FDA’s Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products; Draft Guidance for Industry issued on March 13, 2024.

May 13, 2024

CHPA released the below statement today following Governor Phil Scott signing S. 187 into law this week, legislation that will allow students to carry and self-apply sunscreen at school with the permission of a parent or guardian.

May 8, 2024

CHPA released the below statement today following Tennessee Governor Bill Lee's recent signing of Senate Bill 2048 into law, legislation that raises the monthly purchase limit for common over-the-counter (OTC) cold and allergy medications containing the ingredient pseudoephedrine (PSE) from 5.76 grams per month to 7.2 grams, allowing access to a full 30-day supply per month. The bill also raises the annual purchase limit to 43.2 grams, which is a 40% increase from the current limit of 28.8 grams.

May 7, 2024

CHPA Response to Study Published in Neurology Clinical Practice, Examining Prescription Acid Reflux Drugs:

Apr 25, 2024

In recent years, the issue of consumer data privacy has become increasingly important as technology continues to advance, and more personal information is collected and shared online. Despite the growing concerns over data privacy, the federal government has yet to enact comprehensive legislation addressing the issue. This lack of federal action has prompted many states to take matters into their own hands and introduce their own data privacy laws to protect their residents.

Apr 16, 2024

(WASHINGTON, D.C.) – Representatives from the Consumer Healthcare Products Association (CHPA), Sanofi Consumer Healthcare, Haleon, Kenvue, and Bayer participated in a discussion this week hosted by U.S. Rep. Bob Latta (OH-05) to provide an analysis of the over-the-counter (OTC) Monograph Drug User Fee Program (OMUFA), how some OTCs come to market through the Rx-to-OTC-switch process, how these products are regulated by the U.S. Food and Drug Administration (FDA), and industry’s efforts to expand HSA/FSA coverage for dietary supplements and oral care products.

Apr 11, 2024

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following the adoption of Kentucky House Bill 386 into law, legislation that will eliminate the state’s annual purchase limit for common over-the-counter (OTC) cold and allergy medications containing the ingredient pseudoephedrine (PSE), which is currently the most restrictive yearly limit nationwide at 24 grams, or roughly a three-month supply.

Apr 8, 2024

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the following statement today following West Virginia Governor Jim Justice signing Senate Bill (SB) 688 into law. This legislation lifts the annual purchasing limits for common over-the-counter cold and allergy

Mar 6, 2024

“Consumers can be confident that over-the-counter (OTC) acne products containing benzoyl peroxide (BPO) are stable and safe under the specified storage conditions on their labels.

Mar 6, 2024

Filter Results